ClinicalTrials.gg
CompletedNCT00485433Updated Mar 2, 2021Results posted

Dose-ranging Study for Postoperative Analgesia in Subjects Undergoing Primary Unilateral Inguinal Hernia Repair

A Phase 2 interventional study of Bupivacaine HCl and SKY0402 in Postoperative Pain, sponsored by Pacira Pharmaceuticals, Inc. Completed at 7 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-02.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
114th of 364
98 · median 70
Started
2007
with 6 others
Phase 2
43 of 364
4 open now
Registered
5th of 364
by date
Lead sponsor
22 of 364
Pacira Pharmaceuticals, Inc

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 114th largest by enrollment, is one of 7 that started in 2007, is one of 43 in phase 2, and was the 5th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate three dose levels of SKY0402 compared with 105 mg of bupivacaine HCl.

Read the detailed description

Effective postoperative pain control is a critical element in patient recovery, as the majority of patients may experience significant pain, particularly in the first few days following surgery. Appropriate postoperative pain management contributes to improved healing, faster patient mobilization, shortened hospital stays, and reduced healthcare costs.

03

Conditions studied

  • Postoperative Pain

Keywords

  • hernia
  • unilateral
  • postoperative
  • analgesia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males 18 years of age and older at the Screening Visit.
  2. Scheduled to undergo, elective, primary, unilateral, open-technique, tension-free (Lichtenstein-type technique with mesh) inguinal hernia repair under general anesthesia.
  3. American Society of Anesthesiology (ASA) Physical Class 1-3.
  4. Capable and willing to comply with all study visits and procedures and to provide written .
  5. Able to speak, read, and understand the language of the informed consent form, study questionnaires, and other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to pain scales and other required study assessments.

Exclusion criteria

Exclusion Criteria:

  1. Use of any of the following medications within the times specified before surgery:

    • Long-acting opioid medication within 3 days.
    • Any opioid medication within 24 hours.
  2. Concurrent painful physical condition that may require analgesic treatment in the postoperative period for pain that is not strictly related to the hernia repair procedure and may confound the postoperative assessments (e.g., rheumatoid arthritis, neuropathic pain, concomitant vasectomy).
  3. Body weight less than 50 kilograms.
  4. History of or idiosyncratic reaction to amide-type local anesthetics.
  5. Other to bupivacaine.
  6. Contraindication(s) to epinephrine, such as concurrent administration of monoamine oxidase (MAO) inhibitors or antidepressants of amitriptyline or imipramine types, conditions where the production or exacerbation of tachycardia could prove fatal (e.g., poorly controlled thyrotoxicosis or severe heart disease), or any other pathological conditions that might be aggravated by the effects of epinephrine.
  7. Contraindication to any of the pain control agents anticipated to be used postoperatively (i.e., acetaminophen or oxycodone).
  8. Administration of an product within 30 days or 5 elimination half-lives of such investigational product, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
  9. Suspected or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
  10. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, may interfere with study assessments or compliance.
  11. Current or historical evidence of any condition that, in the opinion of the Investigator, may increase the risk of surgery, complicate the subject's postoperative course, or indicate an increased vulnerability to study drugs and procedures and expose the subject to an unreasonable risk as a result of participating in this clinical trial.

    If during surgery the following criterion is met:

  12. Any clinically significant event or condition uncovered during the hernia repair surgery (e.g., excessive bleeding) that might render the subject medically unstable or complicate the subject's postoperative course.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
98 participants (actual)

Study arms

  • Active comparator
    Bupivacaine HCl 105mg

    Bupivacaine HCl given during hernia repair

    Drug: Bupivacaine HCl

  • Experimental
    SKY0402 low dose

    SKY0402 low dose given during hernia repair

    Drug: SKY0402

  • Experimental
    SKY0402 Middle dose

    SKY0402 middle dose given during hernia repair

    Drug: SKY0402

  • Experimental
    SKY0402 High dose

    SKY0402 high dose given during hernia repair

    Drug: SKY0402

Interventions

  • Bupivacaine HCl given during hernia repair

    Also known as: Marcaine 0.25% with epinephrine 1:200,000

  • SKY0402 given during hernia repair

    Also known as: EXPAREL

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores From 0 Through 72 Hours

    The subject's pain intensity was to be assessed with activity (NRS-A), after the subject had moved himself from a supine position in bed to a sitting up position at the edge of the bed. The subject was to respond to the following question: "On a scale of 0 to 10, where 0=no pain and 10=worst possible pain, how much pain did you have while sitting up?"

    Time frame: 0 to 72 hours

Secondary outcomes

  1. Number of Participants With Adverse Events Through 96 Hours or Serious Adverse Events Through 30 Days

    Time frame: Up to 30 days

07

Results

Posted Aug 6, 2013

Participant flow

Participant flow — Overall Study
MilestoneBupivacaine HCl 105mgSKY0402 Low DoseSKY0402 Middle DoseSKY0402 High Dose
Started24252425
Completed24252425
Not completed0000

Outcome measures

PrimaryArea Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores From 0 Through 72 Hours

The subject's pain intensity was to be assessed with activity (NRS-A), after the subject had moved himself from a supine position in bed to a sitting up position at the edge of the bed. The subject was to respond to the following question: "On a scale of 0 to 10, where 0=no pain and 10=worst possible pain, how much pain did you have while sitting up?"

Time frame:
0 to 72 hours
Reported as:
Mean · Units on a scale*hours
Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores From 0 Through 72 Hours
Units on a scale*hoursBupivacaine HCl 105mgSKY0402 Low DoseSKY0402 Middle DoseSKY0402 High Dose
Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores From 0 Through 72 Hours298.1 ± 136.6286.9 ± 146.4274.6 ± 115.4274.4 ± 253.4
SecondaryNumber of Participants With Adverse Events Through 96 Hours or Serious Adverse Events Through 30 Days
Time frame:
Up to 30 days

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bupivacaine HCl 105mg—0/24 (0%)10/24 (41.7%)
SKY0402 (All Doses)—1/74 (1.4%)17/74 (23%)
Most frequent serious events
Most frequent serious events
EventBupivacaine HCl 105mgSKY0402 (All Doses)
ScarInjury, poisoning and procedural complications0/241/74
Most frequent other events
Most frequent other events
EventBupivacaine HCl 105mgSKY0402 (All Doses)
NauseaGastrointestinal disorders5/246/74
ConstipationGastrointestinal disorders2/247/74
DizzinessNervous system disorders2/246/74
HypoaesthesiaNervous system disorders2/241/74
BradycardiaCardiac disorders0/244/74

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Bupivacaine HCl 105mgSKY0402 Low DoseSKY0402 Middle DoseSKY0402 High DoseTotal
<=18 years00000
Between 18 and 65 years2119182179
>=65 years366419
Age, Continuous
Age, Continuous(years)Bupivacaine HCl 105mgSKY0402 Low DoseSKY0402 Middle DoseSKY0402 High DoseTotal
Mean47.3 ± 16.951.2 ± 17.354 ± 15.152.1 ± 15.651.1 ± 16.2
Sex: Female, Male
Sex: Female, Male(Participants)Bupivacaine HCl 105mgSKY0402 Low DoseSKY0402 Middle DoseSKY0402 High DoseTotal
Female00000
Male2425242598
Region of Enrollment
Region of Enrollment(participants)Bupivacaine HCl 105mgSKY0402 Low DoseSKY0402 Middle DoseSKY0402 High DoseTotal
United States2425242598
08

Study locations

7 sites
  • Arcadia Methodist Hospital
    Arcadia, California 91007, United States
  • Saddleback Valley Outpatient Surgery
    Laguna Hills, California 92653, United States
  • Huntington Memorial Hospital
    Pasadena, California 91105, United States
  • St. Luke's Roosevelt Hosptial Center
    New York, New York 10025, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Memorial Hermann Healthcare System
    Houston, Texas 77024, United States
  • Kirby Outpatient Surgical Center
    Houston, Texas 77054, United States
09

References and documents

Publications

  • Dasta J, Ramamoorthy S, Patou G, Sinatra R. Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting. Curr Med Res Opin. 2012 Oct;28(10):1609-15. doi: 10.1185/03007995.2012.721760. Epub 2012 Sep 3. PubMed 22900785 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Dec 2007 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 5 years 8 months after primary completion. A results delay was requested in Aug 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2007
First posted
Jun 13, 2007
Start
Jun 2007
Primary completionActual
Dec 2007
CompletionActual
Aug 2008
Results delay requested
Aug 25, 2010
Results first posted
Aug 6, 2013
Last update
Mar 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00485433
Responsible party
Sponsor
First posted
Jun 13, 2007
Start date
Jun 2007
Primary completion
Dec 2007
Completion
Aug 2008
Results posted
Aug 6, 2013
Last update
Mar 2, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion